Feasibility and acceptability of an evidence-informed digital intervention to support self-management in people with non-alcoholic fatty liver disease: protocol for a non-randomised feasibility study (VITALISE)

被引:1
|
作者
Avery, Leah [1 ,2 ]
Smith, Hollie [1 ]
McPherson, Stuart [2 ,3 ,4 ]
Hallsworth, Kate [2 ,3 ,4 ]
机构
[1] Teesside Univ, Sch Hlth & Life Sci, Middlesbrough, England
[2] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, England
[3] Newcastle Tyne Hosp NHS Fdn Trust, Liver Unit, Newcastle Upon Tyne, England
[4] NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne, England
关键词
Non-alcoholic fatty liver disease; NAFLD; Lifestyle behaviour change; Diet; Physical activity; Weight loss; Supported self-management; Digital intervention; Feasibility study; NAFLD; PROGRESSION;
D O I
10.1186/s40814-023-01286-2
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BackgroundNon-alcoholic fatty liver disease (NAFLD) represents a spectrum of disease ranging from simple fatty liver to non-alcoholic steatohepatitis, cirrhosis, liver cancer and liver failure. NAFLD affects up to 30-40% of adults in Western countries and is directly linked to overweight and obesity. There are no approved drugs to specifically target NAFLD, therefore weight loss achieved through changes in dietary and physical activity behaviours is the recommended management approach. However, achieving and sustaining weight loss is challenging for patients with NAFLD. We developed a NAFLD-specific digital lifestyle intervention (VITALISE) to target changes in dietary and physical activity behaviours of patients with NAFLD to initiate weight loss and weight loss maintenance. This study aims to evaluate the feasibility and acceptability of VITALISE in a secondary care clinical setting.MethodsA single-centre, one-arm, prospective design will be used to assess the feasibility and acceptability of recruitment, uptake, engagement and completion of VITALISE. Health-related outcomes will be assessed at baseline and 6-months. An interim measure of self-reported weight, physical activity and self-efficacy will be recorded at 12-weeks. Qualitative semi-structured interviews conducted at 6 months follow up will further explore acceptability and feasibility and fidelity of receipt and enactment. The study aims to recruit 35 patients with newly diagnosed NAFLD over a 6-month time period. Eligible patients will have continuous access to VITALISE and monthly tele-coaching support for 6 months prior to follow-up with a hepatologist.DiscussionVITALISE offers access to evidence and theory-informed tailored dietary and physical activity support for patients with NAFLD. The intervention is designed for use by patients in their own time, outside of the hospital setting to overcome well documented challenges including attending additional appointments, and lack of time during routine appointments to adequately address lifestyle behaviour change. This feasibility study will determine the feasibility of VITALISE to support clinical care delivery.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] The feasibility of delivering the ADVANCE digital intervention to reduce intimate partner abuse by men receiving substance use treatment: protocol for a non-randomised multi-centre feasibility study and embedded process evaluation
    Gilchrist, Gail
    Landau, Sabine
    Dheensa, Sandi
    Henderson, Juliet
    Johnson, Amy
    Love, Beverly
    Potts, Laura
    Radcliffe, Polly
    Zenasni, Zohra
    Parrott, Steve
    Li, Jinshuo
    Thomson, Kate
    Dwyer, Georges-Jacques
    Turner, Richard
    Halliwell, Gemma
    Berbary, Cassandra
    Bergman, Ciara
    Feder, Gene
    Easton, Caroline
    Brooks, Cat Papastavrou
    Gilchrist, Elizabeth
    PILOT AND FEASIBILITY STUDIES, 2022, 8 (01)
  • [32] Sustained Improvements in Liver Fat Reduction and Cardiometabolic Health at Nine Months After a 12 Week Digital Health Program in Individuals With Non-Alcoholic Fatty Liver Disease - A Feasibility Study
    Bjornsdottir, Sigridur
    Ulfsdottir, Hildigunnur
    Gudmundsson, Elias F.
    Dobies, Bartosz
    Sveinsdottir, Kolbrun
    Isberg, Ari P.
    Bjornsdottir, Gudlaug
    Sigurdsson, Sigurdur
    Oddsson, Saemundur
    Gudnason, Vilmundur
    CIRCULATION, 2024, 149
  • [33] The feasibility of T2 mapping in the assessment of hepatic steatosis, inflammation, and fibrosis in patients with non-alcoholic fatty liver disease: a preliminary study
    Idilman, I. S.
    Celik, A.
    Savas, B.
    Idilman, R.
    Karcaaltincaba, M.
    CLINICAL RADIOLOGY, 2021, 76 (09) : 709.e13 - 709.e18
  • [34] Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study
    Iwaki, Michihiro
    Kessoku, Takaomi
    Tanaka, Kosuke
    Ozaki, Anna
    Kasai, Yuki
    Yamamoto, Atsushi
    Takahashi, Kota
    Kobayashi, Takashi
    Nogami, Asako
    Honda, Yasushi
    Ogawa, Yuji
    Imajo, Kento
    Yoneda, Masato
    Kobayashi, Noritoshi
    Saito, Satoru
    Nakajima, Atsushi
    BMJ OPEN, 2022, 12 (07):
  • [35] Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study
    Vilar-Gomez, Eduardo
    Athinarayanan, Shaminie J.
    Adams, Rebecca N.
    Hallberg, Sarah J.
    Bhanpuri, Nasir H.
    McKenzie, Amy L.
    Campbell, Wayne W.
    McCarter, James P.
    Phinney, Stephen D.
    Volek, Jeff S.
    Chalasani, Naga
    BMJ OPEN, 2019, 9 (02):
  • [36] A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL
    Mir, Bilal A.
    Sharma, Brij
    Sharma, Rajesh
    Bodh, Vishal
    Chauhan, Ashish
    Majeed, Tahir
    Haq, Inaamul
    Sharma, Neetu
    Sharma, Dikshant
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2024, 14 (05)
  • [37] Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone
    Bradshaw, Daniel
    Gilleece, Yvonne
    Verma, Sumita
    Abramowicz, Iga
    Bremner, Stephen
    Perry, Nicky
    BMJ OPEN, 2020, 10 (07):
  • [38] Delivery of a telehealth supported home exercise program with dietary advice to increase plant-based protein intake in people with non-alcoholic fatty liver disease: a 12-week randomised controlled feasibility trial
    Freer, Christine L.
    George, Elena S.
    Tan, Sze-Yen
    Abbott, Gavin
    Daly, Robin M.
    BRITISH JOURNAL OF NUTRITION, 2024, 131 (10) : 1709 - 1719
  • [39] Hepatic fibrosis in people with HIV and non-alcoholic fatty liver disease: baseline data from an open-label, feasibility randomised trial of maraviroc plus optimised background therapy (OBT) versus OBT alone
    Bradshaw, D.
    Abramowicz, I.
    Bremner, S.
    Gilleece, Y.
    Fedele, S.
    Kirk, S.
    Clarke, C.
    Williams, S.
    Jennings, L.
    Scanlon, D.
    Lambert, P.
    Verma, S.
    Orkin, C.
    Nelson, M.
    Gompels, M.
    Fox, A.
    Clarke, E.
    Chadwick, D.
    Perry, N.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 76 - 77
  • [40] Delivery of a telehealth supported home exercise program with dietary advice to increase plant-based protein in people with non-alcoholic fatty liver disease: a 12-week pilot feasibility randomised controlled trial
    Freer, C.
    George, E.
    Tan, S-y.
    Abbott, G.
    Daly, R.
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2024, 83 (OCE1)